AFC-HD AMS Life ScienceAFC-HD AMS Life Science Co.,Ltd.2927東証スタンダード食料品FY ending Aug 2025, consolidated, J-GAAP

AFC-HD AMS Life Science revenue and profit

Out of every ¥100 of sales, about ¥7 is left as operating profit. Revenue changed +8.2% from the prior year, operating profit +25.8%.

Five-year trend

Revenue¥32.7B
FY ending Aug 2021: ¥22.4B¥22.4BFY ending Aug 2022: ¥23B¥23BFY ending Aug 2023: ¥25.6B¥25.6BFY ending Aug 2024: ¥30.2B¥30.2BFY ending Aug 2025: ¥32.7B¥32.7BFY21FY22FY23FY24FY25
Operating income¥2.41B
FY ending Aug 2021: ¥2.25B¥2.25BFY ending Aug 2022: ¥1.02B¥1.02BFY ending Aug 2023: ¥1.64B¥1.64BFY ending Aug 2024: ¥1.92B¥1.92BFY ending Aug 2025: ¥2.41B¥2.41BFY21FY22FY23FY24FY25
Operating margin7.4%
FY ending Aug 2021: 10.0%10.0%FY ending Aug 2022: 4.4%4.4%FY ending Aug 2023: 6.4%6.4%FY ending Aug 2024: 6.3%6.3%FY ending Aug 2025: 7.4%7.4%FY21FY22FY23FY24FY25

What drives ROE

Net margin × asset turnover = ROA; ROA × financial leverage = ROE

Net margin4.4%
Asset turnover0.68×
ROA3.0%
ROA3.0%
Financial leverage3.32×
ROE10.0%

Denominators: average assets and average equity. Derived from reported values; ROE is shown only for positive profit and equity.

Net margin4.4%
2021: 6.7%6.7%2022: 3.2%3.2%2023: 4.3%4.3%2024: 4.1%4.1%2025: 4.4%4.4%2122232425
Asset turnover0.68×
2021: 0.63×0.63×2022: 0.63×0.63×2023: 0.65×0.65×2024: 0.69×0.69×2025: 0.68×0.68×2122232425
ROA3.0%
2021: 4.2%4.2%2022: 2.0%2.0%2023: 2.8%2.8%2024: 2.8%2.8%2025: 3.0%3.0%2122232425
Financial leverage3.32×
2021: 3.02×3.02×2022: 3.02×3.02×2023: 3.09×3.09×2024: 3.27×3.27×2025: 3.32×3.32×2122232425
ROE10.0%
2021: 12.6%12.6%2022: 6.1%6.1%2023: 8.7%8.7%2024: 9.3%9.3%2025: 10.0%10.0%2122232425
PeriodNet marginAsset turnoverROAFinancial leverageROE
20216.7%0.63×4.2%3.02×12.6%
20223.2%0.63×2.0%3.02×6.1%
20234.3%0.65×2.8%3.09×8.7%
20244.1%0.69×2.8%3.27×9.3%
20254.4%0.68×3.0%3.32×10.0%

Financial leverage can raise ROE; a higher value alone does not describe a company's overall condition.

Asset intensity and goodwill

Annual trends in tangible-asset ratios and goodwill balance.

PPE ÷ revenue65.3%
2020: 48.4%48.4%2021: 71.6%71.6%2022: 69.2%69.2%2023: 67.0%67.0%2024: 64.3%64.3%2025: 65.3%65.3%202122232425
PPE ÷ total assets43.8%
2020: 41.3%41.3%2021: 44.8%44.8%2022: 42.6%42.6%2023: 41.7%41.7%2024: 41.3%41.3%2025: 43.8%43.8%202122232425
Goodwill ÷ parent equity12.5%
2021: 12.6%12.6%2022: 10.8%10.8%2023: 9.9%9.9%2024: 16.9%16.9%2025: 12.5%12.5%202122232425
Goodwill balance¥1.87B
2021: ¥1.49B¥1.49B2022: ¥1.34B¥1.34B2023: ¥1.29B¥1.29B2024: ¥2.35B¥2.35B2025: ¥1.87B¥1.87B202122232425

Ratios are derived from reported values. Goodwill is shown only when separately reported; it is not inferred from combined intangible assets. Definition

Investment and working-capital efficiency

Track R&D investment and how long operating capital remains tied up before sales turn into cash.

R&D spending¥143.1M
2020: ¥166.4M¥166.4M2021: ¥163.7M¥163.7M2022: ¥153M¥153M2023: ¥145.1M¥145.1M2024: ¥148.2M¥148.2M2025: ¥143.1M¥143.1M202122232425
R&D / revenue0.4%
2020: 1.1%1.1%2021: 0.7%0.7%2022: 0.7%0.7%2023: 0.6%0.6%2024: 0.5%0.5%2025: 0.4%0.4%202122232425
Receivable days—
2020: 51d51d2021: 37d37d202122232425
Payable days62d
2020: 65d65d2021: 70d70d2022: 86d86d2023: 73d73d2024: 66d66d2025: 62d62d202122232425

R&D is shown only for years with machine-readable disclosure. Days are estimates using year-end receivables, inventory and payables divided by annual revenue or cost of sales; financial companies are excluded.

Income statement (JPY millions)

ItemFY ending Aug 2021FY ending Aug 2022FY ending Aug 2023FY ending Aug 2024FY ending Aug 2025
Revenue22,36823,02525,57930,18532,655
Cost of revenue15,50314,44216,25619,69421,394
Gross profit6,8658,5839,32310,49211,261
SG&A4,6207,5687,6878,5768,852
Operating income2,2451,0151,6361,9162,410
Pretax income2,1581,2351,5461,9112,201
Income tax662498439665732
Net income attributable to owners1,4967351,1031,2521,449
Operating margin10.0%4.4%6.4%6.3%7.4%

Balance sheet (reported items)

Year-end figures from filings. Unreported items are omitted. Interest-bearing debt excludes lease liabilities.

Assets

Cash 23%
Property, plant and equipment 44%
8%
1%
Other assets 24%

Funding

8%
Other liabilities 61%
Equity 31%

Each bar totals 100% of assets; other is the residual.

ItemFY ending Aug 2021FY ending Aug 2022FY ending Aug 2023FY ending Aug 2024FY ending Aug 2025
Cash and equivalents¥8.67B¥10.3B¥11.1B¥12.1B¥11.2B
Total assets¥35.8B¥37.3B¥41.1B¥47B¥48.7B
Net assets¥12.7B¥12.4B¥13.2B¥14B¥15.2B
Share capital¥2.13B¥2.13B¥2.13B¥2.13B¥2.13B
Trade receivables¥2.24B————
Property, plant and equipment¥16B¥15.9B¥17.1B¥19.4B¥21.3B
Intangible assets excluding goodwill¥1.65B¥1.46B¥1.38B¥2.52B¥2.02B
Goodwill¥1.49B¥1.34B¥1.29B¥2.35B¥1.87B
Investment securities¥736.4M¥849M¥540.1M¥588.8M¥568M
Current assets¥15.9B¥17.1B¥19.9B¥22.1B¥22.3B
Current liabilities¥11.8B¥13.2B¥14.9B¥17.6B¥26B
Trade payables¥2.97B¥3.41B¥3.27B¥3.59B¥3.62B
Short-term borrowings¥3.96B¥6.82B¥7.91B¥9.08B¥9.47B
Long-term borrowings¥9.69B¥10.1B¥11.3B¥13.3B¥5.48B
Total liabilities¥23.1B¥24.9B¥27.9B¥33.1B¥33.5B
Non-controlling interests¥743.4M¥6.1M¥48.6M¥24.3M¥123.9M
Equity attributable to owners of parent¥11.8B¥12.3B¥13B¥13.9B¥15B
Retained earnings¥7.42B¥7.88B¥8.59B¥9.42B¥10.4B
Treasury stock-¥141.4M-¥305.4M-¥353.3M-¥275M-¥255.3M

Sources

Show source documents (6)
  • EDINET (FSA Japan)

    有価証券報告書-第45期(2024/09/01-2025/08/31)

    ID S100X6W82025-11-26Open
  • EDINET (FSA Japan)

    有価証券報告書-第44期(2023/09/01-2024/08/31)

    ID S100UT2C2024-11-27Open
  • EDINET (FSA Japan)

    有価証券報告書-第43期(2022/09/01-2023/08/31)

    ID S100SD2P2023-11-28Open
  • EDINET (FSA Japan)

    有価証券報告書-第42期(令和3年9月1日-令和4年8月31日)

    ID S100PQ002022-11-30Open
  • EDINET (FSA Japan)

    訂正有価証券報告書-第41期(令和2年9月1日-令和3年8月31日)

    ID S100N0TK2021-12-08Open
  • EDINET (FSA Japan)

    有価証券報告書-第40期(令和1年9月1日-令和2年8月31日)

    ID S100K8NO2020-11-25Open

Extracted from XBRL: 55 / Derived from other figures: 1

Spotted an error? Report it (corrections keep the original record)

Analyze this page with AI

Markdown with figures, units, periods and sources, ready to paste into ChatGPT or Claude.